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Abstract
Background: Cognitive impairment and cerebrovascular pathology are both frequent with ageing. Cognitive
impairment due to vascular pathology of the brain, termed vascular cognitive impairment (VCI), is one of the most
frequent causes of cognitive impairment in elderly subjects. Thus far, VCI has no specific pharmacological treatment.
Recent observational studies have suggested a protective effect of physical activity in cognition, but adequate
randomised controlled trials (RCT) are lacking.
Methods: AFIVASC is a multi-centre randomised controlled trial, with a 6-month intervention treatment and an
additional follow-up of 6 months, that aims to estimate the impact of 6 months of moderate intensity physical activity
on cognition (the primary outcome) at 6 and 12months in subjects with VCI. Participants are community dwellers with
criteria for VCI without dementia or who have had previous stroke or transient ischaemic attack (TIA). Patients may be
self-referred or referred from a medical appointment. After confirming the inclusion criteria, a run-in period of 1 month
is conducted to access adherence; only after that are subjects randomly assigned (using a computerised program
blinded to clinical details) to two groups (intervention group and best practice usual care group). The intervention
consists of three physical activity sessions of 60min each (two supervised and one unsupervised) per week. The
primary outcome is measured by the presence or absence of decline in cognitive status. Secondary outcomes include
changes in neuro-cognitive measures, quality of life, and functional and motor status. Primary and secondary outcomes
are evaluated at 6 and 12months by investigators blinded to both intervention and randomisation. A required sample
size of 280 subjects was estimated. Statistical analyses will include regression analysis with repeated measures. The
study was approved by the Ethics Committee for Health of Centro Hospitalar de Lisboa Norte (ref. no. 1063/13) and by
the Ethics Committee for Health of Centro Hospitalar do Porto CHP (ref. no. 2016.055(049-DEFI/048-CES)).
Discussion: We aim to show whether or not moderate physical activity has a beneficial impact on cognition, quality of
life, motor, and functional status in people with vascular cognitive impairment, and to generate new insights on the
applicability of implementing physical activity in this specific population.
Trial Registration: ClinicalTrials.gov, NCT03578614 July 6, 2018.
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Background
Cognitive impairment is frequently associated with ageing,
and cerebral vascular pathology is one of its most frequent
causes [1, 2]. Vascular cognitive impairment (VCI) in-
cludes a myriad of clinical conditions having cerebrovas-
cular aetiology in common that ultimately leads to some
degree of cognitive impairment. Cognitive impairment
ranges from single domain impairment, behavioural
changes and mild multi-domain impairments to dementia
(the most severe stage, termed vascular dementia). De-
mentia is characterised by a compromise of several cogni-
tive domains that leads to functional decline (either in the
social, occupational or personal and family context) and
loss in autonomy in performing activities of daily living of
different complexity. In milder forms, cognitive impair-
ment due to vascular aetiology can be difficult to diagnose
since it may be expressed by symptoms which tend to be
linked to ageing and not to memory impairment. Exam-
ples of these symptoms are reduced verbal or motor initia-
tive, psychomotor slowness, difficulty in multi-tasking,
difficulty in planning, sequencing and finalizing actions, or
even behavioural manifestations only (shown as less inter-
est in hobbies or usual activities, and irritability or dis-
tractibility). VCI is caused by a heterogeneous group of
vessel disorders causing different types of vascular lesions
in the brain, from subclinical small vessel disease (includ-
ing white matter changes, lacunes, or microbleeds) to clin-
ically overt stroke [1, 2].
There is no specific treatment for VCI, and pharmaco-
logical trials have thus far generated negative results [3, 4].
Therefore, in the absence of a cure, efforts should be made
to improve research and intervention in vascular risk fac-
tors [4–6]. Physical activity has gained increasing interest
as a non-pharmacological treatment for both primary
prevention and for delaying evolution in cognitive impair-
ments due to vascular disease. In animal studies, physical
activity has been shown to produce several metabolic ef-
fects (increased expression of neurotransmitters, increased
hippocampal cell proliferation and neurogenesis, increased
antioxidant capacity, reduced inflammatory cytokines and
oxidative stress, and improved mitochondrial functioning
and vascular endothelial function), leading to better
neuroplasticity [7]. In human functional and cerebral per-
fusion studies, physical activity was also associated with
improvement in brain functioning [8].
The World Health Organization (WHO) (2010) [9]
and the American College of Sports Medicine (2017)
[10] have produced recommendations on physical activ-
ity. The associations of cardiovascular [11] and cerebro-
vascular diseases [12] also produced recommendations
on physical activity for cardiac and for stroke patients,
respectively. However, data on cognitive disorders are
quite controversial. Recent observational studies suggested
that physical activity could prevent the progression of VCI
[13]. On the other hand, a recent review found no protect-
ive effect of physical activity in cognitive decline [14]. In
the DAPA trial published recently, no beneficial effect was
achieved with physical activity in patients with Alzheimer’s
disease [15]. There have been intervention trials in pa-
tients at high vascular risk without previous stroke but,
with the exception of one study [16] (which did not in-
clude VCI), no benefit was found [17, 18].
Given these contradictory findings, we lack a robust
evidence base to recommend physical activity in VCI.
Furthermore, there are no data on what type, intensity,
and frequency of activity would be necessary to achieve
long-term gains.
We aim to test, through a randomised controlled trial
(RCT), if physical activity has a beneficial impact on
VCI. We hypothesise that regular physical activity of
moderate intensity for at least 6 months will improve
cognitive impairment in subjects with cognitive impair-
ment due to cerebrovascular pathology.
We also aim to evaluate the effect of physical activity on
the quality of life, and on functional and motor status.
Objectives
The primary objective is to conduct an RCT to evaluate the
effect of 6months of physical activity on cognitive perform-
ance in subjects with VCI without criteria of dementia at
inclusion. We aim to evaluate cognitive performance (as
the primary outcome), and quality of life and motor per-
formance and functional status (as secondary outcomes).
Other objectives are to identify the determinants for the
progression of cognitive decline and quality of life in a large
Portuguese sample of subjects with VCI without dementia
and also to evaluate the impact of the engagement in phys-
ical activities in both subjects and informants.
Methods/design
Design
AFIVASC (“physical activity in vascular cognitive impair-
ment’) is a Portuguese multi-centre, randomised parallel
group trial comparing a 6-month intervention of two
moderate physical activity sessions and one unsupervised
moderate physical activity session per week with an add-
itional follow-up of 6 months to evaluate its long-term
impact in comparison with the current best practice
usual care. The Consolidated Standards of Reporting
Trials (CONSORT) statement [19] has been used as a
framework for the development of our methodology
(Fig. 1). To ensure adherence, a run-in period will be
conducted after inclusion. This run-in period consists of
a 4-week period before randomisation during which all
participants are assigned to equal procedures, namely
the educational session and all planned assessments.
After the run-in period, participants are randomised into
two parallel groups (best practice usual care group and the
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intervention group). The best practice usual care group will
receive the standard usual care, but they are allowed to per-
form physical activity by self-initiative, although supervised
physical intervention is not allowed. The control of the
amount of physical activity per week is performed in both
groups through accelerometry. We do not expect to see
high levels of physical activity in the usual care group since
VCI is usually associated with a reduced initiative.
All participants will be followed up for 12months.
Informants (usually family members) are recruited, as is
usual in cognitive studies, to provide additional data since
we expect the sample size to decline over time. Participants,
informants, and exercise physiologists are not blinded to
the treatment, but all baseline and follow-up assessments
(physical, neuropsychological, and radiological) are blinded
to treatment allocation. According to data protection rules,
all data are anonymised. Technicians involved in statistical
analysis will be blinded to treatment allocation.
Participants
Recruitment and study setting
The study is conducted in the University of Lisbon at
the Faculdade de Medicina and Instituto de Medicina
Molecular in Lisbon, and the Hospital de Santo Antó-
nio, Centro Hospitalar do Porto. The Human Kinetics
Faculty (from the University of Lisbon) is a partner of
the study. These centres, both urban and academic,
have experience in the diagnosis and management of
patients with cognitive decline of a vascular aetiology
and in stroke care. Subjects are referred to each
participating centre directly from the community
(participants can be self-presenting, as the study was
advertised in public spaces) or from a medical ap-
pointment (general family doctor in primary care, or
from neurological, mental health, memory clinics, or
hospital settings). Participants can be referred to the
study due to minor cognitive complaints/symptoms or
minor behavioural changes attributed to a cerebrovas-
cular aetiology. Patients can also be referred if they
had a previous stroke or transient ischemic attack
(TIA), even without complaints, if neuropsychological
evaluation showed evidence of any change considered
to be due to a cerebrovascular aetiology. Post-stroke
cognitive impairment is common even after successful
clinical recovery from a stroke episode, and a recent
study showed that at least one cognitive domain was
Fig. 1 Study design. MRI magnetic resonance imaging
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impaired in 83% of cases [20]. Considering TIA, more
than one cognitive domain was impaired in more
than a third of patients 3 months after a TIA [21].
Eligible subjects are contacted by the recruitment team
to further explain the procedures of the study and to
confirm inclusion and exclusion criteria. Written in-
formed consent is given by participants and informants.
This consent allows access to the subject’s clinical re-
cords for research purposes and indicates their willing-
ness to participate in all the activities inherent to the
study. Those remaining eligible and without contraindi-
cations to physical activity are contacted by an investiga-
tor and proceed to baseline assessments.
Inclusion and exclusion criteria
Inclusion criteria
Participants are included if they are 18 years and older
and fulfil the following criteria: 1) provide written in-
formed consent; 2) are fluent in the Portuguese lan-
guage; 3) are able to read and write; 4) have an available,
reliable informant; and 5) show clinical and functional
criteria A and B as below.
Criteria A (any one of the following three):
1. Probable mild cognitive vascular impairment (VCI,
no dementia) [22];
2. Previous ischaemic or haemorrhagic stroke (more
than 6 months before), with modified Rankin score
≤ 2 at baseline and without formal indication for
physiotherapy;
3. TIA (more than 1 month before), diagnosed by a
neurologist or with an identified vascular lesion
(correlated with TIA clinical symptoms) in cerebral
computed tomography (CT)/magnetic resonance
imaging (MRI).
Criteria B: No functional changes, i.e. instrumental ac-
tivity of daily living (IADL) scale = 0 (no item changed,
or one single item with minimal change), according to
the scoring methods of the LADIS study (minimum of
four items applicable) [23] or no cognitive changes re-
garding the suggested Montreal Cognitive Assessment
Test (MoCA) cut-off point for dementia in Portuguese
clinical samples (score < 17) [24].
Exclusion criteria
Subjects cannot be included if they have at least one of
the following: 1) a diagnosis of dementia; 2) stroke with
formal indication for physiotherapy or speech therapy, or
Rankin score ≥ 2; 3) any contraindication for walking,
physical limitation to gait (orthopaedic or of other struc-
tural causes) that compromises physical activity, or other
condition potentially interfering with the active treatment
(e.g. severe arthritis or severe musculoskeletal pain
associated with walking); 4) evidence of neurodegenerative
disease (of aetiology other than vascular), severe mental
disorder (e.g. major depressive episode or psychosis) or
medical disease which could significantly interfere with
the subjects’ participation or with their quality of life (e.g.
cancer, congestive heart failure, or unstable angina).
Study outcomes
The primary outcome measure will be cognitive decline
defined as a dichotomous variable (decline/no decline)
through cognitive status criteria as described in the As-
sessments section below. The secondary outcomes are
changes in neurocognitive scores of at least 1.5 standard
deviation (SD) from baseline to endpoint (using z scores),
a decline in the raw values of neuropsychological tests, in
quality of life, functional and motor status, and falls.
Assessments
All participants attend three visits (baseline and two
follow-up) consisting of clinical neuropsychological, phys-
ical, and functional observations (baseline, 6 months, and
12months). The study schedule is shown in Fig. 2. In
these visits, participants undergo the following assess-
ments: 1) clinical and sociodemographic assessment; 2)
physical activity assessment; 3) accelerometry assessment;
4) neuropsychological assessment; 5) and brain imaging
(MRI scan; this only at baseline). Informants (appointed
by participants as the best available person to provide in-
formation about them) are also interviewed.
In all assessments (baseline and follow-up clinical visits),
the cognitive status of patients is classified into the follow-
ing groups: 1) diagnosis of dementia; and 2) diagnosis of
cognitive impairment with no dementia according to clin-
ical, neuropsychological, and functional criteria. For this
purpose, we used the usual criteria and definitions of the
Diagnostic and Statistical Manual of Mental Disorders
(edition 4 revised; DSM-4TR) [25]. At baseline, patients
could only fulfil VCI without dementia defined as evi-
dence of cognitive impairment and clinical consensus to
identify significantly related vascular features; exclusion of
dementia when impairments were not sufficiently severe
to interfere with social or occupational functioning or
when impairments were more focal than the global re-
quirement for a diagnosis of dementia. For follow-up we
considered the following criteria for subtypes of dementia:
probable Alzheimer disease [26]; probable vascular de-
mentia [27]; subtype of subcortical vascular dementia [28];
frontotemporal dementia [29]; and Lewy body dementia
[30]. The criteria for Alzheimer’s disease with a vascular
component was made when the investigator judged that
the clinical picture presented both aspects of Alzheimer’s
disease and vascular dementia.
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Assessment measures
Participants are interviewed regarding sociodemographic
factors relevant to the study subject and clinical factors,
including cognitive status in a neurological assessment
and functional status evaluation with the modified Ran-
kin scale and the National Institutes of Health Stroke
Scale (NIHSS) [31–33].
Neuropsychological and quality of life assessments
Cognitive evaluation follows the same protocol in all as-
sessments and is applied by a trained neuropsychologist.
It consists of a neuropsychological battery specifically
designed for this study in order to be sensitive for vascu-
lar cognitive deficits and includes the following tests:
The Montreal Cognitive Assessment (MoCA) [34, 35]
for general assessment; Letter cancellation [36] and the
Wechsler Adult Intelligence Scale-Revised (WAIS-R)
Digit Span (forward) [37, 38] for the assessment of
attention and concentration; Verbal Fluency [35], Trail-
Making Test [39–41], Wechsler Adult Intelligence
Scale-3rd edition (WAIS-III), Digit-Symbol [42], and
Stroop Test [43, 44] to assess executive functions; the
California Verbal Learning Test-9 (CVLT-9) [45, 46],
Wechsler Memory Scale (WMS) Visual Reproduction
and Logical Memory subtests [36, 47], and WAIS-R
Digit Span (backward) subtest [36, 37] to assess memory;
and the Alzheimer's Disease Assessment Scale (ADAS)
Naming objects and Following Commands subtests
[48, 49] to assess language. The impact of cognitive
performance on daily living activities is assessed with
the Instrumental Activities of Daily Living (IADL)
[50]; the presence of depressive symptoms and apathy
are assessed using the 15-item Geriatric Depression
Scale [51] and the Apathy Evaluation Scale [52, 53],
respectively.
The quality of life and other specific measures for the
assessment of an individual psychological resources and
the economic impact of the disease are also added in
this protocol. These measures include the Euro Qol-5
[54] and the Quality of Life in Alzheimer’s Disease
(QOL-AD) [55, 56], the 13-item Orientation to Life
Questionnaire to measure Antonovsky’s sense of co-
herence (SOC-13), a health-promoting resource which
strengthens resilience where higher scores indicate an
ability to adapt to stressful situations [57–59], the
Successful Aging Index (SAI) [60], an a priori index
model of successful ageing which was validated with
respect to service use, and the Resources used in De-
mentia Interview (RUD) [61] to collect data on re-
source utilisation to calculate costs of care (healthcare
Fig. 2 Study schedule
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resource utilisation) and time dedicated to caregiving
in dementia.
Physical activity assessment
The Functional Physical Fitness Battery [62] is a simple,
reproducible, readily available tool to assess submaximal
functional capacity and to evaluate the response to inter-
vention. The Six-Minute Walk Test (6MWT) is per-
formed around an 18-m line to measure the distance in
metres walked in 6min. Participants are instructed to
walk at their own pace according to their tolerance to
exercise for 6 min, with rest stops as needed.
The 30-s chair stand assesses lower body strength, which
is needed for numerous tasks such as climbing stairs or
walking. Participants are instructed to sit and stand as fast
as they can in 30 s with arms folded across the chest.
To assess lower body flexibility (which is important for
good posture, normal gait patterns, and for various mobil-
ity tasks, such as getting in and out of a bathtub or car),
the participant is asked to start from a sitting position at
the front of the chair, with one leg extended and hands
reaching toward the toes. The distance in centimetres be-
tween the extended fingers and the tip of the toe are mea-
sured in both legs. To assess upper body (shoulder)
flexibility (which is important in tasks such as combing
one’s hair, putting on overhead garments, and reaching for
a seat belt), the participant is asked to reach over the
shoulder with one hand and up the middle of the back
with the other hand. The distance in centimetres between
the extended middle fingers is measured.
The agility/dynamic balance is assessed by the number
of seconds required to get up from a seated position,
walk 2.44 m, turn, and return to the seated position. In
this framework, it is interesting to measure multiple di-
mensions of balance in different sensory environments;
therefore, the Fullerton Advanced Balance Scale (FAB) is
also applied [63]. The FAB comprises 10 items that are
scored using a 0–4 ordinal scale (only eight items are
used due to safety and functional reasons). In this case,
the highest score possible on the test is 32 points. Items
include standing with the feet together and eyes closed,
reaching forward to retrieve an object (a pencil) held at
shoulder height with an outstretched arm, turn 360 de-
grees in both right and left directions, a tandem walk,
standing on one leg, standing on foam with the eyes
closed, a two-footed jump, and a walk with head turns.
Accelerometry assessment
The physical activity (PA) time of each participant is
assessed by accelerometry (ActiGraph, GT3X+ model). The
accelerometer is a device that measures the acceleration of
normal human movements, ignoring high-frequency vibra-
tions associated with mechanical equipment. All partici-
pants are asked to wear the accelerometer on the right hip,
close to the iliac crest, for a week. The device activation,
download, and processing is performed using Actilife
v.6.13.3 software (ActiGraph, Fort Walton Beach, FL, USA).
The devices are activated on the first day before the inter-
view and data are recorded using the raw mode with a
30-Hz frequency and posteriorly downloaded into 15-s
epochs.
A valid day is defined as having 600min (10 h) or more
of monitor wear and all participants with at least 3 valid
days (including 1 weekend day) are included in the ana-
lyses. Accelerometer counts ≥ 100 counts per minute
(cpm) are classified as PA with additional separation into
light intensity (100–2019 cpm) and moderate-to-vigorous
intensity (≥ 2020 cpm) [64, 65]. There are no cut-offs for
the sedentary time using the three-axial information from
this new generation Actigraph GT3X+ accelerometer;
therefore, we used the previous cut-offs which are based
on the vertical axis only. Compliance with PA recommen-
dations for public health is assessed according to the
WHO recommendations (adults: 150min/week of at least
moderate-to-vigorous intensity defined as ≥ 21.4min/day).
Neuroimaging assessment
Besides confirming eligibility for the study, MRI is fur-
ther used to control for confounders (for instance, infor-
mation on the degree of atrophy, severity, number and
localisation of vascular lesions, and presence of strategic
lesions). MRI uses the following sequences: Fast Spin
Echo, Fast Flair, T1W-3EDGE (MPRAGE), diffusion and
SWI, using a previously defined protocol based on the
LADIS European study [66]. The parameters that are
measured include:
1. Atrophy (Scheltens evaluation, score 1–8 for global
atrophy and 0–4 for temporal lobe atrophy) [67];
2. White matter change evaluation using Modified
Fazekas scale for severity (score 1–3) [68] and
Scheltens scale for localisation of the lesions [67];
3. Number and localisation of microbleeds (SWI
sequences);
4. Number and localisation of lacunes;
5. Description of previous infarcts and intracerebral
haemorrhages and silent infarcts.
MRI is conducted on the total sample at baseline. In all
centres the MRI machine will have the same power (3 T).
To check for adhesion to the MRI protocol and the
quality of scans, the performance of a dummy run will
be required before the start of the study. For validation,
the representative images of the dummy run will be
checked centrally before start inclusion, and corrections
will be made if necessary.
MRI will have a central reading, blinded to the clinical
details, conducted by the responsible neuroradiologist. A
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clinical neurologist (JMF) not involved in the clinical as-
sessment will also review the images blinded to the clin-
ical results.
Run-in period and follow up assessments
The use of a pre-randomisation run-in period aims to
ensure the engagement and adherence of subjects and to
reduce bias associated with different levels of knowledge
concerning expected benefits of the intervention. Over
4 weeks there is an educational group session, where the
structure of the study, the benefits of physical activity,
and the accelerometry report are explained.
Follow-up assessments will be conducted by clinicians
(neurologist, neuropsychologist, and exercise physiolo-
gist not involved in the intervention sessions and
blinded to the arm).
Randomisation and masking
After the 4-week run-in period, research personnel not
involved in the recruitment, assessment, or intervention
are responsible for managing the randomisation process
using a statistical program. The randomisation sequence
is generated by R software [69]. Participants are ran-
domly assigned (1:1) to either the intervention group
(IG) or to the best practice usual care group (CG), strati-
fied by gender.
All follow-up assessments (physical, neuropsycho-
logical, and clinical diagnosis), and also the neuroradio-
logical evaluation, are blinded to treatment allocation, as
well as in the data set registry.
Intervention
Usual care
All participants receive usual care according to national
guidelines. The Direção Geral da Saúde (DGS) only has
guidelines for the elderly and not for subjects with VCI.
In these guidelines, physical activity is recommended
without further specification [70]. When clinically rele-
vant problems are identified, the doctor in charge of the
patient will be contacted for subsequent guidance.
Experimental intervention and implementation
In the intervention group, three physical activity sessions
are planned per week (two supervised and one unsuper-
vised) conducted over 6 months. In the first 2 months,
the supervised sessions have 10min of warm-up plus 5
min active pause (balance, agility, and coordinative
exercises) plus 15 min walking plus 5 min active pause
(resistance exercises, 1 series of 12 repetitions, three
callisthenic exercises) plus 15 min walking plus 5 min
flexibility (1 series of 10 s in three different postures).
The aimed intensity in these first 2 months is 12/13. Be-
tween the second and fourth months, the duration of
the walking period increases, as well as the intensity
(rating of perceived exertion (RPE) 13/14). The session
consists of 10min of warm-up plus 5min active pause
(balance, agility, and coordinative exercises) plus 20min
walking plus 5min active pause (resistance exercises, 1
series of 15 repetitions, three callisthenic exercises) plus 15
min walking plus 5min flexibility (1 series of 10 s in three
different postures). Between months 4 and 6, the duration
of the walking period again increases, as well as the inten-
sity (RPE 14/15). The session consists of 10min of
warm-up plus 5min active pause (balance, agility, and
coordinative exercises) plus 25min walking plus 5min of
aerobic functional exercises (1 series of 15 repetitions,
three callisthenic dynamic exercises) plus 20min walking
plus 5min flexibility (1 series of 10 s in three different
postures).
To measure the intensity level of the physical activity,
the Borg rating of perceived exertion (RPE) ranging from
6 (rest) to 20 (maximum effort) is used [71]. Perceived
exertion is how hard you feel your body is working. It is
based on the physical sensations a person experiences
during physical activity, including increased heart rate,
increased respiration or breathing rate, increased sweat-
ing, and muscle fatigue. Although this is a subjective
measure, a person’s exertion rating may provide a fairly
good estimate of the actual heart rate during physical ac-
tivity [71].
For the unsupervised session, participants are asked to
accumulate at least 3 bouts of 10 min walking during the
day, with the RPE according to their training intensity
phase.
Regarding the best practise usual care group, physical
activity counselling is given during the educational ses-
sion before the randomisation based on their accelero-
metry results.
Intervention attendance and adherence
Intervention attendance within the 6 months is recorded
in log sheets at the beginning of each session by the ex-
ercise physiologist responsible for the supervised phys-
ical activity sessions. For the unsupervised physical
activity session, patients are asked in the second session
of each week to report whether they have performed it
or not. Dropouts are registered and, whenever the sub-
jects allow, follow-up is maintained with the same de-
sign, although the subject cancels participation in the
sessions.
Data management and safety
Data management follows the General Data Protection
Regulation and the National Clinical Trial regulation
(Act n° 21/2014, 16 April). Case report forms (CRFs)
only include an anonymised code. Personal identification
or any data leading to personal identification is not dir-
ectly associated with data collection forms. The personal
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identification of subjects and data collection forms are
stored in different locations of the leading centre, and
data is only accessed by the research team.
Adverse events are registered in all scheduled appoint-
ments and reviewed by the exercise physiologist in all
sessions. Adverse events are registered in the CRF.
Serious adverse events are defined in the protocol as ad-
verse events that require hospitalisation, medical inter-
ventions, or implicate significant disability, death, or are
immediately life-threatening. These implicate referral to
the doctor in charge, or to the emergency room if
applicable. We should note that we do not expect to
have relevant serious adverse effects, as the intervention
follow WHO guidelines.
Study supervision and ethics
The Steering Committee includes the principal investi-
gator (AV), the investigator leader in the second centre
(MC), the leader in human kinetics (HSC), and the
neuropsychologist expert leader (SM). Two independent
members make up the data monitoring team (one an ex-
pert in statistics (ACS) and the other a clinician (HB)).
Any protocol modifications are required to be submitted
to the Ethical Committee after discussion within the
Steering Committee. Dissemination of study results is
planned both in scientific and in public sessions.
All procedures of the study and the CRFs, as well as
the consent form, were approved by the Ethics Commit-
tee for Health of the Centro Hospitalar de Lisboa Norte
(ref. no. 1063/13) and by the Ethics Committee for the
Health of Centro Hospitalar do Porto CHP (ref. no.
2016.055(049-DEFI/048-CES)). As the intervention fol-
lows the WHO guidelines, the Ethical Committee did
not consider it necessary to provide compensation in
case of any incident during the study.
Statistics
Sample size
The sample size calculation is based on two sets of data.
In the LADIS observational prospective study, which in-
cluded a similar population [13], there was progression
in cognitive decline in 31% of the initial sample after 1
year of follow-up (200 participants out of 639 partici-
pants included). In the Osaki-Tajiri Project [72], which
studied conversion to dementia in a similar population
and measured different severities of cerebrovascular
pathology (as in our study), odds ratios (ORs) between
2.12 and 6 were found to be implicated in the conver-
sion into vascular dementia. We used an OR of 4 in our
calculation of the expected effect (which is clinically
significant).
Using Open Epi software [73] for sample calculation
in randomised trials, we realised a number of 117 sub-
jects in each arm with 95% confidence intervals (alfa of
0.05) and 80% power, giving a total of 234 subjects to be
recruited. Loss to follow-up is usually 20% in this type of
follow-up study, and thus a total of 280 subjects is esti-
mated as being needed.
Data analysis
Data will be registered according to the Consolidated
Standards of Reporting Trials (CONSORT) guidelines
for randomised controlled trials [19]. We will use
intention-to-treat analyses as the primary analysis with
all participants included according to initial group allo-
cation. For the primary outcome analysis (dependent
variable: cognitive decline according to clinical criteria),
we will conduct a logistic regression analysis. Since the
outcomes are measured at 6 and 12months, we will fit a
generalised estimating equations (GEE) logistic regres-
sion model for the data. The models will adjust for co-
variates which are assumed to interfere with cognition in
the follow-up (age, gender, education, and baseline
MoCA). For secondary outcomes, logistic or linear re-
gression analysis will be used as applicable.
For each of the outcome endpoints (i.e. transition of
cognitive status and change in neuropsychological evalu-
ation through composite or global scores) the change
from baseline to 6 months and 12 months will be
assessed, even though we will consider 12 months as the
primary marker of success.
Observing a statistically significant difference on any
of the outcomes will be considered preliminary evidence
of efficacy. We will also report variances, co-variances,
and effect sizes, as well as sampling feasibility (i.e. ease
of recruitment, recruitment rate, withdrawal rate).
The same qualified statistician involved in the statis-
tical analysis designed the SAP and will independently
review the analysis according to the plan.
Discussion
There is considerable controversy concerning the impact
of physical activity on the prevention of cognitive im-
pairment of vascular aetiology. Most of the existing
evidence is garnered from observational studies, with
considerable heterogeneity of methods and types of
interventions. Physical activity is currently recom-
mended for the prevention of cardiovascular diseases
and is already included in the European Guidelines of
Cardiovascular Prevention and Rehabilitation [11], but
evidence in neurocognitive disorders is lacking. To the
best of our knowledge, there are no previously
published, high-quality parallel control trials on the ef-
fect of physical activity on the cognitive status of people
with cognitive impairment due to cerebral vascular path-
ology. RCTs in other cognitive outcomes (for instance in
Alzheimer’s disease) have generated controversial results
[15]. In the recent DAPA trial [15], physical activity not
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only failed to improve cognitive status, but was associ-
ated with a mild (although not significant) cognitive de-
terioration. Regarding our study, we are aware of some
limitations associated with the characteristics of any ran-
domised controlled trial design, implying a selection of
participants and exposure conditions that, in the end,
may preclude generalisability. Nonetheless, in the ab-
sence of evidence-based interventions/treatments in vas-
cular cognitive impairment, and considering that this is
a highly prevalent pathology, we consider our study
quite relevant. We believe that, in the field of neurocog-
nitive disorders, vascular patients are more likely to
benefit from physical interventions than patients with
other neurodegenerative conditions. We also believe that
if this study shows positive findings we will be able to
deliver a simple and universal preventative treatment
that can be widely disseminated in routine practice. At
the same time, we are interested in determining the im-
pact of physical activity on health-related quality of life
and the motor and functional status of these patients,
variables that have been understudied in this domain. Fi-
nally, we hope to explore the determinants of vascular
cognitive impairment in Portuguese subjects.
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 121 kb)
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